Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
申请人:Miller Scott
公开号:US20080269265A1
公开(公告)日:2008-10-30
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
这项发明涉及使用一组芳基脲类化合物治疗raf介导的疾病,以及用于该疗法的药物组合物。
Rhodium(iii)-catalyzed oxidative mono- and di-olefination of isonicotinamides
作者:Xiaohong Wei、Feng Wang、Guoyong Song、Zhengyin Du、Xingwei Li
DOI:10.1039/c2ob25773d
日期:——
[RhCp*Cl2]2 can catalyze the oxidative coupling of secondary isonicotinamides with activated olefins using Cu(OAc)2 as an oxidant. The selectivity can be controlled by the solvent. In MeCN, the mono-olefination and two-fold oxidation reaction is the major pathway, while in THF this reaction gave mostly diolefination products. In both cases, the coupled products contain an exocyclic CC bond.
INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS
申请人:Dumas Jacques
公开号:US20070244120A1
公开(公告)日:2007-10-18
Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
治疗由raf激酶介导的肿瘤的方法,包括使用取代脲化合物,以及这些化合物本身。
tert-Butoxide-Assisted Amidation of Esters under Green Conditions
作者:Jong Park、Yong-Jin Yoon、Bo Kim、Hyung-Geun Lee、Seung-Beom Kang、Gi Sung、Jeum-Jong Kim、Sang-Gyeong Lee
DOI:10.1055/s-0031-1289622
日期:2012.1
Efficient and green amidation reactions are of great importance. In this work, we demonstrate the tert-butoxide-assisted amidation of esters with amines under ambient conditions. Aliphatic and/or aromatic esters were converted into the corresponding amides under mild conditions in good to excellent yields. It is noteworthy that the reaction is highly efficient, rapid, versatile, green and economical
ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF
申请人:UBE INDUSTRIES, LTD.
公开号:US20160244407A1
公开(公告)日:2016-08-25
An aryloyl(oxy or amino)pentafluorosulfanylbenzene compound having pharmacological action. The aryloyl(oxy or amino)pentafluorosulfanylbenzene compound is represented by general formula (A-I), a pharmaceutically acceptable salt thereof, and a prodrug thereof,
wherein all of parameters represent the same meanings as defined in the specification.